Skip to main content
PortfolioPoseida Therapeutics, Inc.

Poseida Therapeutics: Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

By December 3, 2018March 15th, 2021No Comments